Weill Cornell Myeloma Center

09/23/2026

This , listen to Dr. Mateo Mejia on the Weill Cornell Medicine to learn more about how bispecific t-cell engager, or BiTE, therapy works in and future of this advanced form of :

Podcast Episode · CancerCast · March 20 · 26m

08/06/2026

Dr. Mateo Mejia talked to Medscape about smoldering myeloma, a precursor condition to , and when to intervene and start treatment:

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

07/31/2026

Our Clinical Nurse Manager, Czarina Cecilio, spoke with Oncology Nursing News to share insights on toxicity management for , injection techniques, and how nursing interventions can optimize the patient experience:

Czarina Cecilio, BSN, RN, shares roundtable insights on toxicity management, injection techniques, and the critical role of nursing education.

05/27/2026

Bispecific T-cell engager, or BiTE, therapy brings together T-cells and cells to help the body fight cancer. Drs. Mateo Mejia and Manish Shah discuss how and when this therapy is used to treat + other forms of cancer:

Immunotherapy has transformed cancer treatment over the past decade by boosting the body’s natural defenses to recognize and kill cancer. Immunotherapies work in a variety of different ways and have opened new doors for patients with cancers that were once very difficult to treat.

05/11/2026

Dr. Ruben Niesvizky co-chaired the Highlights of ASH Latin American program in Bogota, Colombia where experts including Dr. Maria DeSancho, Clinical Director of Benign Hematology at Weill Cornell Medicine, discussed impactful from the latest American Society of Hematology annual meeting

05/05/2026

Dr. Victor Zepeda discusses current options and emerging based strategies for patients with smoldering via Oncology Learning Network: https://bit.ly/480Hocc (cc: Lymphoma, Leukemia & Myeloma Congress)

Victor Jimenez Zepeda, MD, discusses the evolving management of patients with high-risk smoldering multiple myeloma.

05/01/2026

Watch Dr. Mateo Mejia talk about emerging therapy approaches for the treatment of high-risk subtypes: https://bit.ly/4tkeyMu (cc: Lymphoma, Leukemia & Myeloma Congress)

Mateo Mejia Saldarriaga, MD, discusses the unmet need in high-risk multiple myeloma, including extramedullary disease, CNS involvement, and plasma cell leukemia.

03/30/2026

Chimeric antigen receptor (CAR) T-cell therapy is another form of cellular that uses a patient’s own immune system to fight . All you need to know, broken down in both English and Spanish: https://bit.ly/3NuSfOh

03/26/2026

Want to find out even more about how bispecific t-cell engager (BiTE) therapy works? This video outlines the process. https://bit.ly/4lPfS74

Bispecific T-Cell engager (BiTE) therapy is a novel immunotherapy approach that helps the body’s immune system target cancer cells. In myeloma, BiTEs have th...

03/24/2026

Listen to Dr. Mateo Mejia on the Weill Cornell Medicine to learn more about how bispecific t-cell engager, or BiTE, therapy works in , including associated side effects and the future of this type of treatment: https://bit.ly/4lH4Kc8

Podcast Episode · CancerCast · March 20 · 1 sec